Back to resultsA Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Active
Phase
Phase 4
Locations
United Kingdom
Study Type
Interventional
Intervention
Dapagliflozin
Standard of Care
Sponsored by
About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Type 2 diabetes mellitus, Randomised, Pragmatic, Standard of Care, Dapagliflozin, FORXIGA
Eligibility Criteria
Inclusion Criteria:
For inclusion in the study patients should fulfil the following criteria at the time of screening:
- Provision of informed consent prior to any study specific procedures
- Females and males aged ≥18 years up to ≤ 75 years
- Diagnosed with Type 2 Diabetes Mellitus.
- Uncontrolled on first-line metformin treatment, defined as ≥8 weeks on maximum tolerated dose of metformin and HbA1c > 6.5%.
- Ability to read and write as judged by the investigator.
Exclusion Criteria:
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
- Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
- Previous enrolment or randomization in the present study
- Age > 75 years
- Pregnancy/active breast feeding at the time of inclusion
- Known moderate to severe renal impairment (eGFR<60ml/min).
- Participation in an interventional clinical trial ≤ 3 months before enrolment.
- Unsuitable to participate on mental health grounds, as judged by the investigator.
- Physician decision to use, as second line treatment, insulin, a GLP1 agonist compound or a SGLT2 inhibitor different from dapagliflozin.
- Presence of any of the characteristics in which the products in study are contraindicated, as per current labels.
Sites / Locations
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site, Alum Rock
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site, Market Square
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Dapagliflozin 10 mg
Standard of Care (SOC)
Arm Description
Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
Outcomes
Primary Outcome Measures
Proportion of patients achieving clinical success as measured by a 4-item composite endpoint.
Proportion of patients achieving clinical success as measured by a 4-item composite endpoint including HbA1c reduction vs. baseline (≥ 0.5%), weight loss vs. baseline (≥ 2 Kg), no reported severe or documented hypoglycaemic events since randomization, and no switching from or adding to the treatment to which the patient was randomized (e.g., dapagliflozin or SOC),at the clinical evaluation that occurs closest to 52 weeks of follow-up (allowing a window of 12 weeks).
Secondary Outcome Measures
HbA1c success (HbA1c reduction vs. baseline ≥ 0.5%) at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
HbA1c reduction
Weight loss success (weight vs. baseline ≥ 2 Kg) at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
Weight Loss success
Severe or documented hypoglycaemic events up to 52 weeks following randomization and separately, up to 104 weeks following randomization (in both cases, allowing a window of 12 weeks).
Documented Hypoglycaemic events
To assess differences between dapagliflozin and SOC in the proportion of patients not switching from or adding to the treatment to which the patient was randomized (
Switching from or adding to the treatment to which the patient was randomized (e.g., dapagliflozin or SOC) up to 52 weeks following randomization and separately, up to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
To assess differences between dapagliflozin and SOC in the change from baseline in HbA1
HbA1c at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
To assess differences between dapagliflozin and SOC in the patients worry related to the risk of hypoglycaemic episodes measured b HFS-II Worry Scale at 6,12, 18 and 24 months
To assess differences between dapagliflozin and SOC in the patients worry related to the risk of hypoglycaemic episodes measured b HFS-II Worry Scale at 6,12, 18 and 24 months
To assess differences between dapagliflozin and SOC in the patients satisfaction with treatment as measured by the DTSQ at 6, 12, 18 and 24 months
To assess differences between dapagliflozin and SOC in the patients satisfaction with treatment as measured by the DTSQ at 6, 12, 18 and 24 months
To assess differences between dapagliflozin and SOC in the patients health related quality of life as measured by SF35v2 at 6, 12, 18 and 24 months
To assess differences between dapagliflozin and SOC in the patients health related quality of life, specifically physical, functioning, role functioning and vitality domains as measured by SF35v2 at 6, 12, 18 and 24 months
To assess differences between dapagliflozin and SOC in the proportion of patients needing antihypertensive escalation (dose up titration, switch and add-on strategies),
Antihypertensive initiation or escalation (dose up titration, switch and add-on strategies), up to 52 weeks following randomization and separately, up to 104 weeks following randomization.
To assess differences between dapagliflozin and SOC in the proportion of patients with diabetic complications:
Proportion of patients with the following diabetic complications:
Heart failure
Gangrene or amputation of the leg, foot or toe
Diabetic ketoacidosis
Cerebrovascular disease
Nonfatal myocardial infarction
Blindness
Neuropathy
To assess differences between dapagliflozin and SOC in the change from baseline in systolic blood pressure (SBP) (mmHg) and diastolic blood pressure (DBP) (mmHg)
To assess differences between dapagliflozin and SOC in the change from baseline in systolic blood pressure (SBP) (mmHg) and diastolic blood pressure (DBP) (mmHg) at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
To assess differences between dapagliflozin and SOC in the change from baseline in eGFR
eGFR (ml/min) at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
To assess differences between dapagliflozin and SOC in the healthcare resource utilization up to 52 weeks following randomization and separately, up to 104 weeks following randomization
Hospitalizations, contacts due to hypoglycaemic events, needing insulin treatment, complications and unscheduled GP visits, up to 52 weeks following randomization and separately, up to 104 weeks following randomization
Full Information
NCT ID
NCT02616666
First Posted
November 17, 2015
Last Updated
May 9, 2023
Sponsor
University of Liverpool
Collaborators
AstraZeneca, Clinical Practice Research Datalink
1. Study Identification
Unique Protocol Identification Number
NCT02616666
Brief Title
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients
Acronym
DECIDE
Official Title
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study)
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 25, 2016 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
June 30, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Liverpool
Collaborators
AstraZeneca, Clinical Practice Research Datalink
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
A trial of patients with type 2 diabetes mellitus to evaluate the comparative effectiveness between dapagliflozin and Standard of Care (SOC)
Detailed Description
A longitudinal, open labelled, pragmatic randomized 104 week multicentre trial of patients with type 2 diabetes mellitus to evaluate the comparative effectiveness between dapagliflozin and Standard of Care (SOC)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Type 2 diabetes mellitus, Randomised, Pragmatic, Standard of Care, Dapagliflozin, FORXIGA
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
632 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dapagliflozin 10 mg
Arm Type
Experimental
Arm Description
Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
Arm Title
Standard of Care (SOC)
Arm Type
Active Comparator
Arm Description
Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
Intervention Type
Drug
Intervention Name(s)
Dapagliflozin
Other Intervention Name(s)
FORXIGA
Intervention Description
The product in study is dapagliflozin (FORXIGA™), 10 mg film-coated tablets, and FORXIGA™ should be prescribed according to the instructions in the SmPC and current practice, including up-titration (if considered appropriate by the investigator). Dapagliflozin will be given in combination with metformin.
Intervention Type
Drug
Intervention Name(s)
Standard of Care
Intervention Description
The comparator arm consists of SOC. The SOC arm can be sulphonylurea (SU) or non-SU treatments. SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin. The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy. Other SGLT-2 inhibitors are excluded. All these treatments are approved in the UK for use in this patient population.
Primary Outcome Measure Information:
Title
Proportion of patients achieving clinical success as measured by a 4-item composite endpoint.
Description
Proportion of patients achieving clinical success as measured by a 4-item composite endpoint including HbA1c reduction vs. baseline (≥ 0.5%), weight loss vs. baseline (≥ 2 Kg), no reported severe or documented hypoglycaemic events since randomization, and no switching from or adding to the treatment to which the patient was randomized (e.g., dapagliflozin or SOC),at the clinical evaluation that occurs closest to 52 weeks of follow-up (allowing a window of 12 weeks).
Time Frame
Assessment of outcome measure will be made at the clinical evaluation that occurs closest to 52 weeks of follow-up (allowing a window of 12 weeks).
Secondary Outcome Measure Information:
Title
HbA1c success (HbA1c reduction vs. baseline ≥ 0.5%) at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
Description
HbA1c reduction
Time Frame
From randomization to 104 weeks of follow up.
Title
Weight loss success (weight vs. baseline ≥ 2 Kg) at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
Description
Weight Loss success
Time Frame
closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks)
Title
Severe or documented hypoglycaemic events up to 52 weeks following randomization and separately, up to 104 weeks following randomization (in both cases, allowing a window of 12 weeks).
Description
Documented Hypoglycaemic events
Time Frame
Up to 52 weeks following randomization and separately, up to 104 weeks following randomization (in both cases, allowing a window of 12 weeks).
Title
To assess differences between dapagliflozin and SOC in the proportion of patients not switching from or adding to the treatment to which the patient was randomized (
Description
Switching from or adding to the treatment to which the patient was randomized (e.g., dapagliflozin or SOC) up to 52 weeks following randomization and separately, up to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
Time Frame
up to 52 weeks following randomization and separately, up to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
Title
To assess differences between dapagliflozin and SOC in the change from baseline in HbA1
Description
HbA1c at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
Time Frame
HbA1c at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closet to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
Title
To assess differences between dapagliflozin and SOC in the patients worry related to the risk of hypoglycaemic episodes measured b HFS-II Worry Scale at 6,12, 18 and 24 months
Description
To assess differences between dapagliflozin and SOC in the patients worry related to the risk of hypoglycaemic episodes measured b HFS-II Worry Scale at 6,12, 18 and 24 months
Time Frame
At 6, 12, 18 and 24 months
Title
To assess differences between dapagliflozin and SOC in the patients satisfaction with treatment as measured by the DTSQ at 6, 12, 18 and 24 months
Description
To assess differences between dapagliflozin and SOC in the patients satisfaction with treatment as measured by the DTSQ at 6, 12, 18 and 24 months
Time Frame
At 6, 12, 18 and 24 months
Title
To assess differences between dapagliflozin and SOC in the patients health related quality of life as measured by SF35v2 at 6, 12, 18 and 24 months
Description
To assess differences between dapagliflozin and SOC in the patients health related quality of life, specifically physical, functioning, role functioning and vitality domains as measured by SF35v2 at 6, 12, 18 and 24 months
Time Frame
At 6, 12, 18 and 24 months
Title
To assess differences between dapagliflozin and SOC in the proportion of patients needing antihypertensive escalation (dose up titration, switch and add-on strategies),
Description
Antihypertensive initiation or escalation (dose up titration, switch and add-on strategies), up to 52 weeks following randomization and separately, up to 104 weeks following randomization.
Time Frame
up to 52 weeks following randomization and separately, up to 104 weeks following randomization.
Title
To assess differences between dapagliflozin and SOC in the proportion of patients with diabetic complications:
Description
Proportion of patients with the following diabetic complications:
Heart failure
Gangrene or amputation of the leg, foot or toe
Diabetic ketoacidosis
Cerebrovascular disease
Nonfatal myocardial infarction
Blindness
Neuropathy
Time Frame
up to 52 weeks following randomization and separately, up to 104 weeks following randomization.
Title
To assess differences between dapagliflozin and SOC in the change from baseline in systolic blood pressure (SBP) (mmHg) and diastolic blood pressure (DBP) (mmHg)
Description
To assess differences between dapagliflozin and SOC in the change from baseline in systolic blood pressure (SBP) (mmHg) and diastolic blood pressure (DBP) (mmHg) at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
Time Frame
Closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks)
Title
To assess differences between dapagliflozin and SOC in the change from baseline in eGFR
Description
eGFR (ml/min) at the clinical evaluation that occurs closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
Time Frame
closest to 52 weeks of follow-up and separately, closest to 104 weeks of follow-up (in both cases, allowing a window of 12 weeks).
Title
To assess differences between dapagliflozin and SOC in the healthcare resource utilization up to 52 weeks following randomization and separately, up to 104 weeks following randomization
Description
Hospitalizations, contacts due to hypoglycaemic events, needing insulin treatment, complications and unscheduled GP visits, up to 52 weeks following randomization and separately, up to 104 weeks following randomization
Time Frame
up to 52 weeks following randomization and separately, up to 104 weeks following randomization.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
For inclusion in the study patients should fulfil the following criteria at the time of screening:
Provision of informed consent prior to any study specific procedures
Females and males aged ≥18 years up to ≤ 75 years
Diagnosed with Type 2 Diabetes Mellitus.
Uncontrolled on first-line metformin treatment, defined as ≥8 weeks on maximum tolerated dose of metformin and HbA1c > 6.5%.
Ability to read and write as judged by the investigator.
Exclusion Criteria:
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
Previous enrolment or randomization in the present study
Age > 75 years
Pregnancy/active breast feeding at the time of inclusion
Known moderate to severe renal impairment (eGFR<60ml/min).
Participation in an interventional clinical trial ≤ 3 months before enrolment.
Unsuitable to participate on mental health grounds, as judged by the investigator.
Physician decision to use, as second line treatment, insulin, a GLP1 agonist compound or a SGLT2 inhibitor different from dapagliflozin.
Presence of any of the characteristics in which the products in study are contraindicated, as per current labels.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John Wilding, MBChB, DM
Organizational Affiliation
Universtiy of Liverpool, University Hospital, Aintree, Longmoor Lane, Liverpool, L9 7AL, UK
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jesús Medina, PhD
Organizational Affiliation
AstraZeneca
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Susan Beatty, MSc
Organizational Affiliation
Clinical Practice Research Datalink
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Forfar
State/Province
Angus
Country
United Kingdom
Facility Name
Research Site
City
Yate
State/Province
Avon
Country
United Kingdom
Facility Name
Research Site
City
Bracknell
State/Province
Berkshire
Country
United Kingdom
Facility Name
Research Site
City
Reading
State/Province
Berkshire
Country
United Kingdom
Facility Name
Research Site
City
Wokingham
State/Province
Berkshire
Country
United Kingdom
Facility Name
Research Site
City
Maesteg
State/Province
Bridgend
Country
United Kingdom
Facility Name
Research Site
City
Chew Stoke
State/Province
Bristol
Country
United Kingdom
Facility Name
Research Site
City
Yate
State/Province
Bristol
Country
United Kingdom
Facility Name
Research Site
City
Iver
State/Province
Bucks
Country
United Kingdom
Facility Name
Research Site
City
Blackwood
State/Province
Caerphilly
Country
United Kingdom
Facility Name
Research Site
City
Greenisland
State/Province
Carrickfergus
Country
United Kingdom
Facility Name
Research Site
City
Whitehead
State/Province
Carrickfergus
Country
United Kingdom
Facility Name
Research Site
City
Macclesfield
State/Province
Cheshire
Country
United Kingdom
Facility Name
Research Site
City
Crook
State/Province
County Durham
Country
United Kingdom
Facility Name
Research Site
City
Denbigh
State/Province
Denbighshire
Country
United Kingdom
Facility Name
Research Site
City
Exeter
State/Province
Devon
Country
United Kingdom
Facility Name
Research Site
City
Hull
State/Province
East Yorkshire
Country
United Kingdom
Facility Name
Research Site
City
Romford
State/Province
Essex
Country
United Kingdom
Facility Name
Research Site
City
Pinhoe
State/Province
Exeter
Country
United Kingdom
Facility Name
Research Site
City
Cheltenham
State/Province
Gloucestershire
Country
United Kingdom
Facility Name
Research Site
City
Trafford
State/Province
Greater Manchester
Country
United Kingdom
Facility Name
Research Site
City
Worsley
State/Province
Greater Manchester
Country
United Kingdom
Facility Name
Research Site
City
Alton
State/Province
Hampshire
Country
United Kingdom
Facility Name
Research Site
City
Farnborough
State/Province
Hampshire
Country
United Kingdom
Facility Name
Research Site
City
Gosport
State/Province
Hampshire
Country
United Kingdom
Facility Name
Research Site
City
Havant
State/Province
Hampshire
Country
United Kingdom
Facility Name
Research Site
City
Romsey
State/Province
Hampshire
Country
United Kingdom
Facility Name
Research Site
City
Southampton
State/Province
Hampshire
Country
United Kingdom
Facility Name
Research Site
City
Waterlooville
State/Province
Hampshire
Country
United Kingdom
Facility Name
Research Site
City
Winchester
State/Province
Hampshire
Country
United Kingdom
Facility Name
Research Site
City
Southampton
State/Province
Hants
Country
United Kingdom
Facility Name
Research Site
City
Leominster
State/Province
Herefordshire
Country
United Kingdom
Facility Name
Research Site
City
Fortrose
State/Province
Highland
Country
United Kingdom
Facility Name
Research Site
City
Beckenham
State/Province
Kent
Country
United Kingdom
Facility Name
Research Site
City
Canterbury
State/Province
Kent
Country
United Kingdom
Facility Name
Research Site
City
Faversham
State/Province
Kent
Country
United Kingdom
Facility Name
Research Site
City
Gravesend
State/Province
Kent
Country
United Kingdom
Facility Name
Research Site
City
Rainham
State/Province
Kent
Country
United Kingdom
Facility Name
Research Site
City
Barnoldswick
State/Province
Lancashire
Country
United Kingdom
Facility Name
Research Site
City
Blackburn
State/Province
Lancashire
Country
United Kingdom
Facility Name
Research Site
City
Darwen
State/Province
Lancashire
Country
United Kingdom
Facility Name
Research Site
City
Lancaster
State/Province
Lancashire
Country
United Kingdom
Facility Name
Research Site
City
Nelson
State/Province
Lancashire
Country
United Kingdom
Facility Name
Research Site
City
Thornton-Cleveleys
State/Province
Lancashire
Country
United Kingdom
Facility Name
Research Site
City
Thornton-Cleveleys
State/Province
Lancs
Country
United Kingdom
Facility Name
Research Site
City
Loughborough
State/Province
Leicestershire
Country
United Kingdom
Facility Name
Research Site
City
Brockley
State/Province
London
Country
United Kingdom
Facility Name
Research Site
City
Rotherhithe
State/Province
London
Country
United Kingdom
Facility Name
Research Site
City
Streatham
State/Province
London
Country
United Kingdom
Facility Name
Research Site
City
Trafford
State/Province
Manchester
Country
United Kingdom
Facility Name
Research Site
City
Liverpool
State/Province
Merseyside
Country
United Kingdom
Facility Name
Research Site
City
Wirral
State/Province
Merseyside
Country
United Kingdom
Facility Name
Research Site
City
Wembley
State/Province
Middlesex
Country
United Kingdom
Facility Name
Research Site
City
Glyncorrwg
State/Province
Neath Port Talbot
Country
United Kingdom
Facility Name
Research Site
City
Swaffham
State/Province
Norfolk
Country
United Kingdom
Facility Name
Research Site
City
Clevedon
State/Province
North Somerset
Country
United Kingdom
Facility Name
Research Site
City
Pickering
State/Province
North Yorkshire
Country
United Kingdom
Facility Name
Research Site
City
Ripon
State/Province
North Yorkshire
Country
United Kingdom
Facility Name
Research Site
City
Nottingham
State/Province
Nottinghamshire
Country
United Kingdom
Facility Name
Research Site
City
Nottingham
State/Province
Notts
Country
United Kingdom
Facility Name
Research Site
City
Bicester
State/Province
Oxfordshire
Country
United Kingdom
Facility Name
Research Site
City
Carterton
State/Province
Oxfordshire
Country
United Kingdom
Facility Name
Research Site
City
Oxford
State/Province
Oxfordshire
Country
United Kingdom
Facility Name
Research Site
City
Wantage
State/Province
Oxfordshire
Country
United Kingdom
Facility Name
Research Site
City
Witney
State/Province
Oxfordshire
Country
United Kingdom
Facility Name
Research Site
City
Oxford
State/Province
Oxon
Country
United Kingdom
Facility Name
Research Site
City
Milford Haven
State/Province
Pembrokeshire
Country
United Kingdom
Facility Name
Research Site
City
Tonypandy
State/Province
Rhondda Cynon Taff
Country
United Kingdom
Facility Name
Research Site
City
Pontypridd
State/Province
Rhondda Cynon Taf
Country
United Kingdom
Facility Name
Research Site
City
Telford
State/Province
Shropshire
Country
United Kingdom
Facility Name
Research Site
City
Axbridge
State/Province
Somerset
Country
United Kingdom
Facility Name
Research Site
City
Ayr
State/Province
South Ayrshire
Country
United Kingdom
Facility Name
Research Site
City
Worsborough
State/Province
South Yorkshire
Country
United Kingdom
Facility Name
Research Site
City
Bury St Edmunds
State/Province
Suffolk
Country
United Kingdom
Facility Name
Research Site
City
Camberley
State/Province
Surrey
Country
United Kingdom
Facility Name
Research Site
City
Guildford
State/Province
Surrey
Country
United Kingdom
Facility Name
Research Site
City
London
State/Province
Surrey
Country
United Kingdom
Facility Name
Research Site
City
Killay
State/Province
Swansea
Country
United Kingdom
Facility Name
Research Site
City
Barry
State/Province
Vale Of Glamorgan
Country
United Kingdom
Facility Name
Research Site
City
Nuneaton
State/Province
Warks
Country
United Kingdom
Facility Name
Research Site
City
Alcester
State/Province
Warwickshire
Country
United Kingdom
Facility Name
Research Site
City
Atherstone
State/Province
Warwickshire
Country
United Kingdom
Facility Name
Research Site
City
Bidford-on-Avon
State/Province
Warwickshire
Country
United Kingdom
Facility Name
Research Site
City
Nuneaton
State/Province
Warwickshire
Country
United Kingdom
Facility Name
Research Site
City
Stratford-upon-Avon
State/Province
Warwickshire
Country
United Kingdom
Facility Name
Research Site
City
Warwick
State/Province
Warwickshire
Country
United Kingdom
Facility Name
Research Site
City
Walsall
State/Province
West Midlands
Country
United Kingdom
Facility Name
Research Site
City
Wolverhampton
State/Province
West Midlands
Country
United Kingdom
Facility Name
Research Site
City
Crawley
State/Province
West Sussex
Country
United Kingdom
Facility Name
Research Site
City
Swindon
State/Province
Wiltshire
Country
United Kingdom
Facility Name
Research Site
City
Droitwich
State/Province
Worcestershire
Country
United Kingdom
Facility Name
Research Site
City
Kidderminster
State/Province
Worcestershire
Country
United Kingdom
Facility Name
Research Site
City
Malvern
State/Province
Worcestershire
Country
United Kingdom
Facility Name
Research Site
City
Alton
Country
United Kingdom
Facility Name
Research Site
City
Altrincham
Country
United Kingdom
Facility Name
Research Site, Alum Rock
City
Birmingham
Country
United Kingdom
Facility Name
Research Site
City
Blackburn
Country
United Kingdom
Facility Name
Research Site
City
Cambridge
Country
United Kingdom
Facility Name
Research Site
City
Cirencester
Country
United Kingdom
Facility Name
Research Site
City
Cockermouth
Country
United Kingdom
Facility Name
Research Site
City
Colchester
Country
United Kingdom
Facility Name
Research Site
City
Colindale
Country
United Kingdom
Facility Name
Research Site
City
Dudley
Country
United Kingdom
Facility Name
Research Site
City
Edmonton
Country
United Kingdom
Facility Name
Research Site
City
Fareham
Country
United Kingdom
Facility Name
Research Site
City
Fleet
Country
United Kingdom
Facility Name
Research Site
City
Gravesend
Country
United Kingdom
Facility Name
Research Site
City
Hull
Country
United Kingdom
Facility Name
Research Site, Market Square
City
Kineton
Country
United Kingdom
Facility Name
Research Site
City
Kings Norton
Country
United Kingdom
Facility Name
Research Site
City
Langport
Country
United Kingdom
Facility Name
Research Site
City
Leamington Spa
Country
United Kingdom
Facility Name
Research Site
City
Liphook
Country
United Kingdom
Facility Name
Research Site
City
Liverpool
Country
United Kingdom
Facility Name
Research Site
City
London
ZIP/Postal Code
N8
Country
United Kingdom
Facility Name
Research Site
City
London
Country
United Kingdom
Facility Name
Research Site
City
Maryport
Country
United Kingdom
Facility Name
Research Site
City
Morriston
Country
United Kingdom
Facility Name
Research Site
City
Newport
Country
United Kingdom
Facility Name
Research Site
City
Oxford
ZIP/Postal Code
OX2
Country
United Kingdom
Facility Name
Research Site
City
Oxford
Country
United Kingdom
Facility Name
Research Site
City
Petersfield
Country
United Kingdom
Facility Name
Research Site
City
Rowlands Castle
Country
United Kingdom
Facility Name
Research Site
City
Stansted
Country
United Kingdom
Facility Name
Research Site
City
Stratford-upon-Avon
Country
United Kingdom
Facility Name
Research Site
City
Torquay
Country
United Kingdom
Facility Name
Research Site
City
Wallsend
Country
United Kingdom
Facility Name
Research Site
City
Waterlooville
Country
United Kingdom
Facility Name
Research Site
City
Wembley
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients
We'll reach out to this number within 24 hrs